IGMS News and Press, IGM Biosciences Inc. From 11/02/23

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

IGM Biosciences Inc. (IGMS) is expected to report $-1.25 for Q3 2023

2023-10-20 17:24:19 ET Gainers: Day One Biopharmaceuticals ( DAWN ) +6% . ContextLogic  ( WISH ) +5% . Vital Farms ( VITL ) +5% . Verona Pharma  ( VRNA ) +4% . GoPro ( GPRO ) +3% . Losers: IGM Biosciences ( IG...

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 pa...

2023-10-04 11:11:30 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences: High OpEx And Underwhelming Monotherapy Data Warrant Caution IGM Bioscience announces departure of chairman Michael Loberg ...

2023-10-03 16:38:40 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences: High OpEx And Underwhelming Monotherapy Data Warrant Caution Seeking Alpha’s Quant Rating on IGM Biosciences Histor...

MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chai...

2023-10-01 06:44:10 ET Summary IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company. IGM-2323, now called imvotamab, has shifted i...

MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside c...

2023-08-03 17:41:02 ET IGM Biosciences press release ( NASDAQ: IGMS ): Q2 GAAP EPS of -$1.43 beats by $0.01 . Revenue of $0.45M (+21.6% Y/Y) misses by $0.34M . For further details see: IGM Biosciences GAAP EPS of -$1.43 beats by $0.01, revenue of $0.45M m...